You have 10 free articles left this month. Get your freeBasic subscription now and gain instant access to more.

UPDATE 1 - Slovenian drug maker Krka's Q1 cons net profit rises 42%

UPDATE 1 - Slovenian drug maker Krka's Q1 cons net profit rises 42% Source: Krka

LJUBLJANA (Slovenia), May 23 (SeeNews) – Slovenian pharmaceuticals producer Krka [LJE:KRKG] reported on Thursday a consolidated net profit of 70.3 million euro ($78.1 million) in the first quarter, up 42% on the year.

Consolidated revenue increased 12% year-on-year to 378.5 million euro in the three months through March, Krka said in a bourse filing.

Krka's region East Europe reached the highest sales figure in the group, of 122.1 million euro or 32.4% of total sales. First-quarter sales in East Europe rose 15% on the year.

The next largest region in terms of sales was Central Europe, where sales revenues increased 6% to 85.9 million euro, or 22.8% of total sales.

Region West Europe followed, generating sales of 84.3 million euro, or a 22.3% share, and showing an increase of 14% on the year.

Sales in South-East Europe expanded 14% to 50.4 million euro (13.4% share), and in Overseas Markets they added 16% to 12.6 million euro (3.3%).

Sales in Slovenia increased to 22.0 million euro, up 3% on the year, or 5.8% of total Krka Group sales.

Krka's consolidated EBITDA amounted to 99.9 million euro at the end of March, up from 90.4 million euro a year earlier, while its EBIT increased to 72.2 million euro form 61.9 million euro.

The Krka Group allocated 23.7 million euro to investments in the first quarter, of which 19.6 million euro to the controlling company.

The group employed 11,370 people at the end of March, down from 11,390 at the end of 2018.

($ = 0.89603 euro)